CD4 and infection: In contrast, another gB-based vaccine trial demonstrated that the levels of gB-specific memory B cells were robust at 24 months, and nAbs in fibroblasts and CD4+ T cells were higher than in natural infection in vaccine recipients for up to 4 years (39).